A Study of PATAS Trifluoroacetate Using Single Ascending Doses in Healthy Volunteers

Part of paid clinical trials in Cincinnati, Ohio.

Sponsor
AdipoPharma LLC
Study ID
NCT07223333
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 55 Years
Healthy Volunteers
Accepted

Interventions

  • PATAS Trifluoroacetate — DRUG
    A drug targeting the interaction between the ALMS1 protein and alpha-PKC
  • Placebo — DRUG
    Excipient only formulation, without active compound

Study Details

The primary objective of this study is to evaluate safety and tolerability of single subcutaneous (SC) doses of PATAS in healthy subjects. The secondary objective of this study is to determine the pharmacokinetics (PK) of single SC doses of PATAS in healthy subjects.

Key Dates

Start date
Jan 27, 2026
Status verified
Jan 2026
Primary completion
Jul 30, 2026
Completion
Sep 30, 2026

Study Design

Enrollment
56 participants (estimated)
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Placebo Comparator: Healthy subjects, Placebo
  • Experimental: Healthy Subjects, Active

Primary Outcome Measure

Safety -- 1A [ Time Frame: 29 days ]

Central Contacts

Locations (2)

FacilityCityStateZIPSite coordinators
Medpace Clinical Pharmacology UnitCincinnatiOhio45227
Medical Director
Medpace Clinical Pharmaology UnitCincinnatiOhio45227-

Find similar trials in Cincinnati, OH

By condition
Type 2 diabetes
By specialty
EndocrinologyMetabolic healthWeight loss
By research site
Medpace Clinical Pharmacology Unit· Cincinnati, OHMedpace Clinical Pharmaology Unit· Cincinnati, OH

Related Studies